Recently, Johnson & Johnson (JNJ) announced that its developed bispecific antibody, Rybrevant (amivantamab), has received full approval from the U.S. FDA for its use in combination with chemotherapy (carboplatin and pemetrexed) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients.

         Winter is the peak season for acute cardiovascular and cerebrovascular events. Cold weather can lead to elevated blood pressure and cerebral vasospasm, increasing the likelihood of cerebrovascular disease. Myocardial infarction and sudden cardiac death are also associated with cold temperatures. Studies have shown that for every 1°C decrease in temperature, the incidence of heart disease increases by approximately 2%. Traditional treatment strategies typically involve methods such as reducing fat, improving metabolism, dilating blood vessels, or clearing vascular blockages. However, these strategies still have many limitations.

         Diabetes, referred to as 'Xiaoke syndrome' in traditional Chinese medicine in China, has been documented in classic Chinese medical texts such as the 'Huangdi Neijing' and 'Lingshu' as early as around 400 BC. It refers to type 2 diabetes mellitus (T2DM), characterized by symptoms such as polydipsia, polyphagia, polyuria, as well as emaciation, fatigue, and sweet urine. According to traditional Chinese medicine, the pathological mechanism of 'Xiaoke syndrome' involves the dysfunction of the lungs, stomach, and kidneys, with the underlying pathology being the consumption of Yin and fluids and an excess of dryness and heat. Symptoms persist for a long time until the condition becomes uncontrollable.

Nanobodies (Nbs) are single-domain antibodies composed of variable heavy-chain domains (VHHs) derived from camelids. Their unique structure and superior properties have positioned them as a research hotspot in the global biopharmaceutical field.